CDC Guidance on Sexually Transmitted Ringworm TMVII
- The Centers for Disease Control and Prevention has issued new clinical guidance regarding Trichophyton mentagrophytes type VII.
- Public health authorities note that TMVII infections are frequently mistaken for traditional sexually transmitted infections or skin conditions like eczema.
- In an official letter to healthcare providers, the CDC advises practitioners to consider TMVII when evaluating patients with skin lesions on or near the genitals, groin, buttocks, perineum,...
The Centers for Disease Control and Prevention has issued new clinical guidance regarding Trichophyton mentagrophytes type VII. This sexually transmitted strain of ringworm has been circulating in the United States since 2024. Federal health officials report that the fungal infection primarily presents as round rashes on the arms, buttocks, trunk, genitals, and legs. Transmission is predominantly associated with sexual activity among men who have sex with men.
Federal Health Officials Track Sexually Transmitted Ringworm Strain
Diagnostic Challenges and Misidentification Risks
Public health authorities note that TMVII infections are frequently mistaken for traditional sexually transmitted infections or skin conditions like eczema. The largest cluster of cases has been identified in Minnesota, where state health officials credited clinicians for recognizing the lesions early and contacting the health department immediately.
Targeted Screening and Patient History Protocols
In an official letter to healthcare providers, the CDC advises practitioners to consider TMVII when evaluating patients with skin lesions on or near the genitals, groin, buttocks, perineum, face, or beard.
Providers are urged to collect a thorough patient history that includes questions about sexual exposure, recent travel, and previous use of over-the-counter creams or ointments.
Extended Treatment Regimens and Agency Support
When clinicians strongly suspect a TMVII infection, the CDC recommends initiating treatment with an oral antifungal drug immediately. Full resolution of the lesions often requires a treatment duration of six to 12 weeks or longer, accompanied by ongoing clinical follow-up.
Healthcare providers seeking assistance with diagnostic testing, reporting, or patient management are directed to contact their local health departments. If a health department identifies a potential outbreak, staff can reach out directly to the CDC via email for support.
Contagion Control and Transmission Prevention
To curb transmission, public health agencies emphasize that any active rash should be treated as highly contagious.
Individuals with symptoms are advised to seek medical care promptly and avoid skin-to-skin contact, including sexual activity, until lesions have completely cleared. Sharing personal items such as towels, bedding, clothing, razors, and sex toys should also be strictly avoided.